Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firibastat in difficult-to-treat or resistant hypertension
2019-004509-29Phase 3Completed
- Sponsor
- Quantum Genomics
- Start
- Mar 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in resistant hypertension (RH) and essential hypertension comparing Firibastat with Placebo (2 arms). Primary endpoint: Change in systolic automated office blood pressure. Started Mar 2020; status: completed.
02
Drugs
firibastat
03
Conditions
resistant hypertension (RH)essential hypertension
Beyond the preview
Go deeper on 2019-004509-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004509-29.